J. Di Martino

Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma

R. Plummer, G. Curigliano, E. Baudin, 2020, Clinical Cancer Research.

Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma.

I. Braña, M. Zuraek, I. Aronchik, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.